Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ULRIC DUNCAN

NPI
1518908854
CMS profile
114520
Location
SOUTHAVEN, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,753.45

157 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,737.34 156
Education $16.11 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ULRIC DUNCAN

NPI 1518908854 · CMS profile ID 114520

SOUTHAVEN, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518908854?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ULRIC DUNCAN, NPI 1518908854, CMS profile ID 114520. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518908854?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ULRIC DUNCAN, NPI 1518908854, CMS profile ID 114520. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518908854?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ULRIC DUNCAN, NPI 1518908854, CMS profile ID 114520, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1518908854?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

157 matching records · $3,753.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 157 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 157.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $18.2105/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049385867 CMS
NESTLE HEALTHCARE NUTRITION INC. $14.1305/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012528025 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.9905/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057379713 CMS
AbbVie Inc. $87.3005/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763623 CMS
Gilead Sciences, Inc. $4.0905/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026141295 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.0405/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057223021 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.1005/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057436467 CMS
AbbVie Inc. $13.6705/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763619 CMS
Janssen Biotech, Inc. $16.4705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988312513 CMS
AbbVie Inc. $18.6404/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763614 CMS
PFIZER INC. $19.5804/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049385623 CMS
AbbVie Inc. $13.8704/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763611 CMS
AbbVie Inc. $9.5804/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763605 CMS
Janssen Biotech, Inc. $19.2104/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988312477 CMS
E.R. Squibb & Sons, L.L.C. $97.6204/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016175057 CMS
AbbVie Inc. $14.2604/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763601 CMS
Gilead Sciences, Inc. $27.7204/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025584465 CMS
Janssen Biotech, Inc. $14.3504/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988312503 CMS
AbbVie Inc. $14.3504/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763591 CMS
AbbVie Inc. $124.8404/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763595 CMS
RedHill Biopharma Inc. $17.3103/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996695469 CMS
AbbVie Inc. $11.3903/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763577 CMS
AbbVie Inc. $14.7403/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763581 CMS
AbbVie Inc. $119.7103/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763585 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.6503/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057263175 CMS
Janssen Biotech, Inc. $20.7403/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988312467 CMS
AbbVie Inc. $11.0703/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763571 CMS
NESTLE HEALTHCARE NUTRITION INC. $15.1503/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012469151 CMS
AbbVie Inc. $12.0003/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763567 CMS
Celgene Corporation $13.4803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016175085 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.6103/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057208093 CMS
AbbVie Inc. $12.1103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763561 CMS
Janssen Biotech, Inc. $15.8603/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988312555 CMS
AbbVie Inc. $18.0603/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763557 CMS
Gilead Sciences, Inc. $20.9003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025783867 CMS
AbbVie Inc. $117.9402/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763551 CMS
Ironwood Pharmaceuticals, Inc $17.0802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045549017 CMS
AbbVie Inc. $12.1202/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763547 CMS
AbbVie Inc. $13.2302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763545 CMS
Janssen Biotech, Inc. $15.0702/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988312457 CMS
NESTLE HEALTHCARE NUTRITION INC. $17.6602/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012492987 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.9602/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055381459 CMS
AbbVie Inc. $1.5202/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763535 CMS
AbbVie Inc. $12.1502/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996763539 CMS
Janssen Biotech, Inc. $10.6402/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988312545 CMS
Gilead Sciences, Inc. $20.8601/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025785109 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.7601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055381457 CMS
INTERCEPT PHARMACEUTICALS, INC. $17.6601/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837421 CMS
PFIZER INC. $8.5801/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049129293 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.1901/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057263485 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,025.59 72
PY2020 $1,361.50 101
PY2021 $1,561.11 101
PY2022 $2,438.89 105
PY2023 $3,753.45 157
PY2024 $5,888.21 175
PY2025 $4,507.37 187

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $967.24 6
PY2025 Principal investigator $106,097.50 20
PY2024 Principal investigator $19,100.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,000.00 12/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223290076
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/12/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 12/12/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289642
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 12/12/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289644
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,750.00 12/12/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289646
Principal investigator 1 Genentech, Inc. $1,147.50 12/09/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LL
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211664307
Principal investigator 1 Genentech, Inc. $4,000.00 11/04/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664378
Principal investigator 1 Genentech, Inc. $4,000.00 09/18/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211664905
Recipient ABBVIE INC. $60.00 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202398002
Recipient ABBVIE INC. $70.00 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202398005
Recipient ABBVIE INC. $25.00 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202398008
Recipient ABBVIE INC. $458.18 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202398011
Recipient ABBVIE INC. $204.06 08/21/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202397994
Recipient ABBVIE INC. $150.00 08/21/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202397998
Principal investigator 1 ABBVIE INC. $16,750.00 06/03/2025 Non-covered Recipient Entity
CANDUN RESEARCH INSTITUTE INC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202487945
Principal investigator 1 ABBVIE INC. $3,500.00 05/22/2025 Non-covered Recipient Entity
CANDUN RESEARCH INSTITUTE INC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202485909
Principal investigator 1 ABBVIE INC. $7,500.00 05/15/2025 Non-covered Recipient Entity
CANDUN RESEARCH INSTITUTE INC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202485131
Principal investigator 1 Genentech, Inc. $1,600.00 04/15/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211664688
Principal investigator 1 Genentech, Inc. $13,500.00 04/15/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211664744
Principal investigator 1 Genentech, Inc. $2,500.00 04/15/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211664794
Principal investigator 1 Genentech, Inc. $1,600.00 04/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211664715
Principal investigator 1 Genentech, Inc. $2,000.00 04/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211664739
Principal investigator 1 Genentech, Inc. $2,500.00 04/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211664769
Principal investigator 1 Genentech, Inc. $13,500.00 04/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211664777
Principal investigator 1 Genentech, Inc. $5,000.00 04/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211664782
Principal investigator 1 Genentech, Inc. $5,000.00 01/28/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211664684